*  Somatostatin-induced paradoxical increase in intracellular Ca2+ concentration and insulin release in the presence of arginine...
Somatostatin, a hormone that signals via Gi/Go, usually inhibits increases in intracellular calcium concentration ([Ca2+]i) and insulin release from β-cells. We have found that in the presence of arginine vasopressin (AVP), which signals via Gq, somatostatin increased [Ca2+]i, leading to insulin release in HIT-T15 cells. The increase in [Ca2+]i by somatostatin was observed even after 60min of AVP treatment. Somatostatin alone failed to increase [Ca2+]i and insulin release. Somatostatin induced changes in [Ca2+]i in a biphasic pattern, characterized by a sharp and transient increase followed by a rapid decline to sub-basal levels. Pretreatment with pertussis toxin, which inactivates Gi/Go, abolished the effects of somatostatin. U-73122, an inhibitor of phospholipase C, antagonized the somatostatin-induced increase in [Ca2+]i. In Ca2+-free medium, somatostatin still increased ...
  http://www.biochemj.org/content/364/1/33
*  Somatostatin analogues for reducing complications following pancreatic surgery | Cochrane
Pancreatic resections are associated with high morbidity (30% to 60%) and mortality (5%). It is not clear whether routine, preventive use of synthetic analogues of somatostatin (a hormone that inhibits pancreatic secretions) could reduce complications following pancreatic surgery. We included 21 randomised clinical trials in this review. All trials had high risk of bias ('systematic error'). A total of 2348 people were randomised either to somatostatin analogues or a control in the 21 trials. The overall number of people with postoperative complications was lower by 30% in the somatostatin analogues group but there was no difference in postoperative mortality, re-operation rate or overall length of hospital stay between the groups. Pancreatic fistula is drainage of pancreatic juice secreted by the remaining pancreas to the exterior. This was lower in the intervention group by 34%. The proportion of these fistulas that resulted in change to the treatment ...
  http://www.cochrane.org/CD008370/UPPERGI_somatostatin-analogues-for-reducing-complications-following-pancreatic-surgery
*  Sabinet | The effects of somatostatin on hormonal and metabolic responses in chronic pancreatitis
Unmodified synthetic somatostatin, given as a 200-ug intravenous bolus, plus 200 ug infused over 3 hours, had no effect on basal plasma insulin and pancreatic glucagon-like immunoreactivity (GLI) levels, both in controls and in patients with chronic pancreatitis.
  http://journals.co.za/content/m_samj/51/24/AJA20785135_24735
*  JCI - Welcome
Somatostatin secreted by pancreatic δ cells mediates important paracrine interactions in Langerhans islets, including maintenance of glucose metabolism through the control of reciprocal insulin and glucagon secretion. Disruption of this circuit contributes to the development of diabetes. However, the precise mechanisms that control somatostatin secretion from islets remain elusive. Here, we found that a super-complex comprising the cullin 4B-RING E3 ligase (CRL4B) and polycomb repressive complex 2 (PRC2) epigenetically regulates somatostatin secretion in islets. Constitutive ablation of CUL4B, the core component of the CRL4B-PRC2 complex, in δ cells impaired glucose tolerance and decreased insulin secretion through enhanced somatostatin release. Moreover, mechanistic studies showed that the CRL4B-PRC2 complex, under the control of the δ cell-specific transcription factor hematopoietically expressed homeobox (HHEX), determines the levels of ...
  https://m.jci.org/tags/20
*  Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin.
Using a continuous subcutaneous octreotide infusion to create constant supraphysiological somatostatinergic tone, we have previously shown that growth hormone (GH) pulse generation in women is independent of endogenous somatostatin (SRIH) declines. G
  http://www.biomedsearch.com/nih/Pulsatile-nocturnal-growth-hormone-secretions/12670836.html
*  Plus it
This study examines the effect of muscimol, a high affinity, specific gamma-aminobutyric acid (GABA) agonist, on glucose-stimulated somatostatin and insulin release from the isolated, perfused rat pancreas. Perfusion with low glucose (50 mg/dl) conditions resulted in basal somatostatin release of 46 ± 4 pg/ml. Basal insulin release was less than 20 μU/ml. High glucose (300 mg/dl) conditions stimulated somatostatin and insulin release. Steady-state levels of somatostatin and insulin release under high glucose conditions were 425 ± 12 pg/ml and 419 ± 18 μU/ml, respectively. Perfusion with medium containing 1 μM muscimol inhibited glucose-stimulated somatostatin release by 38%, whereas the course of glucose-stimulated insulin release was unaffected. Tentative conclusions from this study are (1) that GABA is potentially a modulator of islet somatostatin but not insulin release, and (2) the fact that ...
  http://diabetes.diabetesjournals.org/content/30/2/168
*  Plus it
Somatostatin's release from the isolated rat pancreas was studied using a perfusion technique. Arginine at a concentration of 19 mM produced a biphasic increase in somatostatin release from the perfused rat pancreas. Both first and second phases of somatostatin's increase are significantly higher in the presence of 1 mM theophylline than in the absence of the drug. These results indicate the possible inclusion of the adenylate cyclase-cyclic AMP system in the regulatory mechanism of rat pancreatic somatostatin secretion.. ...
  http://diabetes.diabetesjournals.org/content/28/5/457
*  Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. - Full...
This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. All patients at their scheduled visits will have drug dispensing information and reported adverse events and serious adverse events collected.. A patient will reach the end of study when pasireotide treatment is permanently discontinued and the end of treatment visit has been performed. All patients must be followed up for safety evaluations for 3 months following the last dose of pasireotide LAR treatment and for 1 month following the last dose of pasireotide s.c. treatment.. The study is expected to remain open for approximately 10 years or until such time that enrolled patients no longer need treatment with pasireotide or are able to obtain commercial supply ...
  https://clinicaltrials.gov/ct2/show/NCT01794793?cond=%22familial+isolated+pituitary+adenoma%22+OR+%22Pituitary+Neoplasms%22&rank=20
*  Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. - Full...
This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. All patients at their scheduled visits will have drug dispensing information and reported adverse events and serious adverse events collected.. A patient will reach the end of study when pasireotide treatment is permanently discontinued and the end of treatment visit has been performed. All patients must be followed up for safety evaluations for 3 months following the last dose of pasireotide LAR treatment and for 1 month following the last dose of pasireotide s.c. treatment.. The study is expected to remain open for approximately 10 years or until such time that enrolled patients no longer need treatment with pasireotide or are able to obtain commercial supply ...
  https://clinicaltrials.gov/ct2/show/NCT01794793?term=novartis&rank=10
*  Lirias: The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and...
TT-232 is a somatostatin analogue containing a five-residue ring structure. The present report describes TT-232-induced signalling events in A431 cells, where a 4-h preincubation with the peptide irreversibly induced a cell death program, which involves DNA-laddering and the appearance of shrunken nuclei, but is unrelated to somatostatin signalling. Early intracellular signals of TT-232 include a transient two-fold activation of the extracellular signal-regulated kinase (ERK2) and a strong and sustained activation of the stress-activated protein kinases c-Jun NH(2)-terminal kinase (JNK)/SAPK and p38MAPK. Blocking the signalling to ERK or p38MAPK activation had no effect on the TT-232-induced cell killing. At the commitment time for inducing cell death, TT-232 decreased EGFR-tyrosine phosphorylation and prevented epidermial growth factor (EGF)-induced events like cRaf-1 and ERK2 activation. Signalling to ERK activation by FCS, phorbol 12-myristate 13-acetate (PMA) and ...
  https://lirias.kuleuven.be/handle/123456789/10294
*  Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy...
The role of somatostatin analogues (SSTa) in the treatment of acromegaly. To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive
  http://www.biomedsearch.com/nih/Long-term-up-to-18/17524029.html
*  Patent US20040181032 - Somatostatin antagonists - Google Patents
The present invention is directed to a somatostatin antagonist according to formula (I), wherein A1 is an optionally substituted aromatic ∝-amino acid; A2 is an optionally substituted aromatic ∝-amino acid; A3 is Dab, Dap, Lys or Orn; A4 is β-Hydroxyvaline, Ser, Hser, or Thr; A5 is an optionally substituted D- or L-aromatic -amino acid; and Y1 is OH, NH2 or NHR1, where R1 is (C1-6)alkyl; wherein each said optionally substituted aromatic -amino acid is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, NO2, OH, CN, (C1-6)alkyl, (c2-6)alkenyl, (c2-6)alkynyl, (C1-6)alkoxy, Bzl, O-Bzl, and NR9R10, where R9 ad R10 each is independently H, O, or (C1-6)alkyl; and wherein the amine nitrogen of each of amide peptide bond and the amino group of A1 of formula (I) is optionally substituted with a methyl group, provided that there is at least one said methyl group; or a pharmaceutically acceptable salt thereof, and to uses thereof.
  http://www.google.com/patents/US20040181032?dq=5958006
*  Peptidic Nanoparticles for Cancer Therapy and Diagnosis
Somatostatin peptides such as somatostatin 28 or 14 are known for their high binding affinity to G-coupled peptide receptors, which are often over-expressed on tumor cells. Using this binding property we developed a new type of functional peptidic nanoparticles based on Somatostatin for tumor targeting and drug delivery. Somatostatin 28 and 14 were genetically incorporated into the nanoparticles and in addition they will be radiolabeld with radionuclides (technetium-99m for example). Because targeting peptides can easily be introduced into the sequence of the nanoparticles forming peptide, this new technology can be regarded as a plattform for the design of a variety of tumor-targeting motifs.
  http://nsti.org/procs/Nanotech2005v1/3/W54.02
*  Physiology of somatostatin and its analogues
Somatostatin holds an interesting place in gastrointestinal endocrinology. Originally discovered as an inhibitor of growth hormone release, it is now known to inhibit a variety of gastrointestinal processes () . Somatostatin is produced by paracrine
  http://www.uptodate.com/contents/physiology-of-somatostatin-and-its-analogues
*  Somatostatin R4/SSTR4 Research Products: Novus Biologicals
Somatostatin R4/SSTR4 products available through Novus Biologicals. Browse our Somatostatin R4/SSTR4 product catalog backed by our Guarantee+.
  https://www.novusbio.com/common-name/somatostatin-r4-sstr4
*  ValiScreen Somatostatin sst2a (human) cell line | PerkinElmer
Stable recombinant cell line expressing the Somatostatin, sst2a receptor. Human recombinant, in CHO-K1 host cell. We provide: Two vials of the recombinant cell line as frozen cells; Detailed product information including sequence, cell line properties, culture conditions, pharmacological properties of the recombinant receptor in binding and functional assays (cAMP ...
  https://www-punchout.perkinelmer.com/product/somatostatin-sst2a-human-cell-line-es-521-c
*  ValiScreen Somatostatin sst3 (human) cell line | PerkinElmer
Stable recombinant cell line expressing the Somatostatin, sst3 receptor. Human recombinant, in CHO-K1 host cell. We provide: Two vials of the recombinant cell line as frozen cells; Detailed product information including sequence, cell line properties, culture conditions, pharmacological properties of the recombinant receptor in binding and functional assays (cAMP ...
  http://www.perkinelmer.com/product/somatostatin-sst3-human-cell-line-es-523-c
*  Somatostatin sst4 AequoScreen cell line | PerkinElmer
AequoScreen® Double Transfected Cell Lines: Somatostatin, sst4 subtype. Human Recombinant, in CHO-K1 host cell. Two vials of cryopreserved cells are shipped per order. A detailed technical dossier includes sequence, culture conditions and pharmacological properties of the recombinant receptor. All cell lines are tested for the absence of mycoplasma. Terms and conditions apply. Some products are not available in some countries. Please inquire at your local sales office for more information.. Features:. ...
  http://www.perkinelmer.com/product/somatostatin-sst4-aequoscreen-cell-line-es-524-a
*  somatostatin Global Market and Forecast Research : ReportsnReports
[65 Pages Report] Check for Discount on somatostatin Global Market and Forecast Research report by ChemReport. DescriptionWe provide independent and unbiased information on manufacturers, prices, production...
  http://www.reportsnreports.com/reports/599577-somatostatin-global-market-and-forecast-research.html
*  Effects of angiopeptin on transplant arteriosclerosis in the rat
The influence of the somatostatin analogue angiopeptin on transplant arteriosclerosis was investigated using two aortic transplantation rat models. One was characterized by ischemia/reperfusion-induced changes in syngeneic transplants while immunologically induced changes dominated in the other allogeneic model. Angiopeptin, 100 micrograms/kg per day, was administered continuously until the sacrifice of the rats after 8 weeks. No additional immunosuppression was used in either model. An image analysis system was used to quantify the intimal and medial thicknesses of the grafts. In the syngeneic grafts, the intimal thickness was less than 50% of that of control grafts (P , 0.05), but no difference was seen in the allogeneic model. The expression of selected cells, TGF-beta s, and PDGF and PDGF alpha-receptors was detected immunohistochemically and displayed a similar picture in control and angiopeptin-treated grafts in both models. We conclude that angiopeptin has no clear immunosuppressive ...
  http://umu.diva-portal.org/smash/record.jsf?pid=diva2:865896
*  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? |...
Gallium-68 is a metallic positron emitter with a half-life of 68 min that is ideal for the in vivo use of small molecules, such as [68Ga-DOTA,Tyr3]octreotide, in the diagnostic imaging of somatostatin
  https://link.springer.com/article/10.1007%2Fs00259-006-0317-x
*  Somatostatin - Answers on HealthTap
There's a lot to it: B"sd an endocrinologist is always interested in sandostatin a long acting brand orf octreotide: is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone". It has a number of other actions and classicaly a medical rx of acromegally. Certainly, glad to discuss in more detail. ...Read more ...
  https://www.healthtap.com/topics/somatostatin
*  Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133.
Abstract In this paper, we demonstrate that phosphorylation of CREB at Ser-133 is induced 6-fold in vivo, following treatment of PC12 cells with forskolin. By contrast, no such ind..
  https://www.omicsonline.org/references/cyclic-amp-stimulates-somatostatin-gene-transcription-by-phosphorylation-of-creb-at-serine-133-1075964.html
*  China Lab Supply GMP Standard Peptide Powder Somatostatin for Bulking Sale Photos & Pictures - Made-in-china.com
Lab Supply GMP Standard Peptide Powder Somatostatin for Bulking Sale picture from Shenzhen Simeiquan Biotechnology Co., Ltd. view photo of Weight Loss, Vitamin, Chemical.Contact China Suppliers for More Products and Price.
  http://simeiquan.en.made-in-china.com/productimage/CXiERDpThOhu-2f1j00qAFQvnPIwhkO/China-Lab-Supply-GMP-Standard-Peptide-Powder-Somatostatin-for-Bulking-Sale.html